Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.
about
PAR2-mediated upregulation of BDNF contributes to central sensitization in bone cancer pain.Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawalIn vivo efficacy of enabling formulations based on hydroxypropyl-β-cyclodextrins, micellar preparation, and liposomes for the lipophilic cannabinoid CB2 agonist, MDA7.Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.Enhanced analgesic activity by cyclodextrins - a systematic review and meta-analysis.Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain.Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.Corticotropin-releasing factor mediates bone cancer induced pain through neuronal activation in rat spinal cord.Referred symptom from myofascial pain syndrome: One of the most important causes of sensory disturbance in breast cancer patients using taxanes.Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post-ischemic pain model of complex regional pain syndrome type I in rats.Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models
P2860
Q33637280-2B14632F-7958-4DFC-BEE7-1479C5FF9E7CQ34403197-77A3031A-876B-4452-A221-CB8791772EB4Q37695142-EE626AB7-E37E-485E-851B-6F81BA8D2577Q37721641-B3D285B1-64FE-4B4F-91C9-487CBD28DA36Q38212376-7C4BEA1D-902E-4333-B305-7E4CC314D618Q38544457-849358EF-A44C-4531-A19D-D24499A849B0Q39668102-6E69EF36-FF8F-407E-A9B6-4A7FF0D9D9F6Q41562602-E1FC10B7-0BC7-42C2-BED0-D4393F2F9C5FQ41665044-C786A634-845F-459F-92BD-E9DE83862E6DQ47159191-7D9D1915-1971-420D-9176-0E77E7E44465Q48078831-41920AC8-8BF5-4170-B3F1-346367B72142Q50995839-C76F12C7-7380-465E-ACB6-DFC00E7F540EQ51417508-29B71D6C-8E62-4367-A601-B8E936E247DDQ57174777-6AAEC86F-9811-4F55-932D-9222BE855647
P2860
Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prevention of paclitaxel-induc ...... binoid type 2 receptor system.
@ast
Prevention of paclitaxel-induc ...... binoid type 2 receptor system.
@en
type
label
Prevention of paclitaxel-induc ...... binoid type 2 receptor system.
@ast
Prevention of paclitaxel-induc ...... binoid type 2 receptor system.
@en
prefLabel
Prevention of paclitaxel-induc ...... binoid type 2 receptor system.
@ast
Prevention of paclitaxel-induc ...... binoid type 2 receptor system.
@en
P2093
P2860
P921
P1476
Prevention of paclitaxel-induc ...... binoid type 2 receptor system.
@en
P2093
David Cogdell
David L Brown
Jianhua Hu
Jijun J Xu
Mohamed Naguib
Philippe Diaz
Suzanne Craig
Walter N Hittelman
P2860
P304
P356
10.1213/ANE.0B013E31824B0191
P407
P577
2012-03-05T00:00:00Z